GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Suven Life Sciences Ltd (NSE:SUVEN) » Definitions » EV-to-EBIT

Suven Life Sciences (NSE:SUVEN) EV-to-EBIT : -31.05 (As of May. 30, 2025)


View and export this data going back to 2003. Start your Free Trial

What is Suven Life Sciences EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Suven Life Sciences's Enterprise Value is ₹49,894.16 Mil. Suven Life Sciences's EBIT for the trailing twelve months (TTM) ended in Mar. 2025 was ₹-1,606.98 Mil. Therefore, Suven Life Sciences's EV-to-EBIT for today is -31.05.

The historical rank and industry rank for Suven Life Sciences's EV-to-EBIT or its related term are showing as below:

NSE:SUVEN' s EV-to-EBIT Range Over the Past 10 Years
Min: -32.76   Med: -5.07   Max: 8.7
Current: -31.04

During the past 13 years, the highest EV-to-EBIT of Suven Life Sciences was 8.70. The lowest was -32.76. And the median was -5.07.

NSE:SUVEN's EV-to-EBIT is ranked worse than
100% of 688 companies
in the Drug Manufacturers industry
Industry Median: 16.935 vs NSE:SUVEN: -31.04

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Suven Life Sciences's Enterprise Value for the quarter that ended in Mar. 2025 was ₹24,187.66 Mil. Suven Life Sciences's EBIT for the trailing twelve months (TTM) ended in Mar. 2025 was ₹-1,606.98 Mil. Suven Life Sciences's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2025 was -6.64%.


Suven Life Sciences EV-to-EBIT Historical Data

The historical data trend for Suven Life Sciences's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Suven Life Sciences EV-to-EBIT Chart

Suven Life Sciences Annual Data
Trend Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -11.15 -10.71 -8.27 -19.68 -15.01

Suven Life Sciences Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -19.68 -20.87 -19.73 -19.35 -15.01

Competitive Comparison of Suven Life Sciences's EV-to-EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Suven Life Sciences's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Suven Life Sciences's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Suven Life Sciences's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Suven Life Sciences's EV-to-EBIT falls into.


;
;

Suven Life Sciences EV-to-EBIT Calculation

Suven Life Sciences's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=49894.161/-1606.984
=-31.05

Suven Life Sciences's current Enterprise Value is ₹49,894.16 Mil.
Suven Life Sciences's EBIT for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹-1,606.98 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Suven Life Sciences  (NSE:SUVEN) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Suven Life Sciences's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2025 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Mar. 2025 ) =EBIT / Enterprise Value (Q: Mar. 2025 )
=-1606.984/24187.66358
=-6.64 %

Suven Life Sciences's Enterprise Value for the quarter that ended in Mar. 2025 was ₹24,187.66 Mil.
Suven Life Sciences's EBIT for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹-1,606.98 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Suven Life Sciences EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Suven Life Sciences's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Suven Life Sciences Business Description

Traded in Other Exchanges
Address
Avenue 7, Road No. 5, Banjara Hills, Number 8-2-334, 6th Floor, SDE Serene Chambers, Hyderabad, TG, IND, 500 034
Suven Life Sciences Ltd is an India-based biopharmaceutical company. The company is focused on the acquisition, development, and commercialization of novel therapeutics for the treatment of neurodegenerative disorders. The company's only segment is providing Research and Development services. The company's geographical segment includes India; the USA; Europe and Others. The company generates maximum revenue from the USA. The company earns revenue from the sale of New Chemical Entity (NCE) based Intermediates for CNS disorders.

Suven Life Sciences Headlines

No Headlines